Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 32.77 kDa 
• Atom Count: 2151 
• Modelled Residue Count: 256 
• Deposited Residue Count: 287 
• Unique protein chains: 1

2IN6

Wee1 kinase complex with inhibitor PD311839

• DOI: 10.2210/pdb2IN6/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens
• Expression System: Spodoptera frugiperda
• Mutation(s): No 


• Deposited: 2006-10-05 Released: 2007-09-18 
• Deposition Author(s): Squire, C.J., Dickson, J.M., Ivanovic, I., Baker, E.N.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Free: 0.299 
• R-Value Work: 0.248 
• R-Value Observed: 0.250 

Literature

Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases.

Smaill, J.B., Baker, E.N., Booth, R.J., Bridges, A.J., Dickson, J.M., Dobrusin, E.M., Ivanovic, I., Kraker, A.J., Lee, H.H., Lunney, E.A., Ortwine, D.F., Palmer, B.D., Quin, J., Squire, C.J., Thompson, A.M., Denny, W.A.

(2008) Eur J Med Chem 43: 1276-1296

• PubMed: 17869387 
• DOI: 10.1016/j.ejmech.2007.07.016
• Primary Citation of Related Structures:  
  2IN6, 2IO6


• PubMed Abstract: 
  

A series of N-6 substituted 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones were prepared from N-substituted (5-methoxyphenyl)ethenylindoles. The target compounds were tested for their ability to inhibit the G2/M cell cycle checkpoint kinases, Wee1 and Chk1. Analogues with neutral or cationic N-6 side chains were potent dual inhibitors. Acidic side chains provided potent (average IC(50) 0.057 microM) and selective (average ratio 223-fold) Wee1 inhibition. Co-crystal structures of inhibitors bound to Wee1 show that the pyrrolo[3,4-c]carbazole scaffold binds in the ATP-binding site, with N-6 substituents involved in H-bonding to conserved water molecules. HT-29 cells treated with doxorubicin and then target compounds demonstrate an active Cdc2/cyclin B complex, inhibition of the doxorubicin-induced phosphorylation of tyrosine 15 of Cdc2 and abrogation of the G2 checkpoint.

---

Related Citations: 

• Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation.
  Squire, C.J., Dickson, J.M., Ivanovic, I., Baker, E.N.
  (2005) Structure 13: 541

---

Organizational Affiliation: 

Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1020, New Zealand. [e-mail]

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Wee1-like protein kinase	A	287	Homo sapiens	Mutation(s): 0  Gene Names: WEE1 EC: 2.7.10.2
UniProt & NIH Common Fund Data Resources
Find proteins for P30291 (Homo sapiens) Explore P30291  Go to UniProtKB:  P30291
PHAROS:  P30291 GTEx:  ENSG00000166483

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
839	B [auth A]	3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID C23 H16 N2 O5 JDARUOOLJCFUOY-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
839	IC50:  23   nM  Binding MOAD
839	IC50 :  23   nM  PDBBind
839	IC50:  23   nM  BindingDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Free: 0.299 
• R-Value Work: 0.248 
• R-Value Observed: 0.250 
• Space Group: P 4₁ 2₁ 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 69.465	α = 90
b = 69.465	β = 90
c = 157.344	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
HKL-2000	data reduction
HKL-2000	data scaling
AMoRE	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2006-10-05 
• Released Date: 2007-09-18 
Deposition Author(s): Squire, C.J., Dickson, J.M., Ivanovic, I., Baker, E.N.

Revision History  

• Version 1.0: 2007-09-18
  Type: Initial release
  
• Version 1.1: 2011-07-13
  Changes: Version format compliance